Case Study

The investment covers two expansions to accommodate several pipeline products moving to commercial scale

ADCelerate is Piramal Pharma Solutions’ rapid approach to delivering Phase-Iappropriate ADC drug substance and drug product, so that you can acceleratethe delivery of your product to patients in the clinic. From project initiation toGMP drug product in as little as 12 months, with no compromising on quality

The move is expected to bring added value to customers by coupling biology services with existing chemistry capabilities

Patient Centricity @ Piramal Pharma Solutions

Transaction adds new technologies and capabilities in large molecules, including vaccines and gene therapy, to its global offering

Recent Updates and Future Plans for Piramal Pharma Solutions

The acquisition will add peptide API development and manufacturing capabilities- Peptide drugs are growing significantly in oncology and metabolic therapies- Piramal’s integrated drug substance and drug product offering will now include peptides

Transition to Differentiated Offerings and Value to Consumer

The expansion adds both additional capacity and new capabilities in labs and manufacturing- Growing customer demand in the API space is driving the investment- The investment is further validation of the company’s commitment to patients around the world

Piramal Pharma Solutions- V Block, Pithampur, India

The work will be performed at Piramal Pharma Solutions’ development and manufacturing site in Lexington, KentuckyMSA covers work on Plus Therapeutics’ RNL-Liposome Intermediate Drug Product

As part of our market-leading expertise in drug substances, Piramal Pharma Solutions offers multigram to kilogram GMP peptides for clinical trials and a deep portfolio of generic peptide APIs. Our GMP manufacturing capabilities include 4,500 liters of reactor volume, while our non-GMP R&D facility features more than twenty scientists with vast experience in peptide chemistry. It’s another example of how we are continually expanding the ways in which we help reduce the burden of disease on patients

Piramal Pharma Solutions (PPS) is providing drug product formulation and manufacturing from the company’s Lexington, KY site in the U.S. Drug product material will be used in a first-in-humans clinical study

API sites and Formulation Sites 

Piramal Enterprise Limited completes the integration of its pharma businesses into its subsidiary - Piramal Pharma Limited Carlyle completes investment in Piramal Pharma; capital infusion to accelerate Piramal Pharma’s organic and inorganic growth plans
Carlyle’s global healthcare expertise to bring significant value to Piramal Pharma 

Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.

SOLVENT EFFICIENCYIMPROVEMENT INITIATIVE

Delivering Integrated Solutions Across The Drug Life Cycle